The global DNA and gene cloning services market was valued at USD 2.51 billion in 2023 and is projected to reach USD 6.82 billion by 2030, expanding at a strong CAGR of 15.43% between 2024 and 2030. The growth of this market is largely fueled by rapid advancements in DNA and gene cloning technologies, the growing acceptance of gene therapy as a treatment option, and the increasing demand for personalized medicine tailored to individual genetic profiles. Gene cloning plays a crucial role in modern biotechnology as it allows researchers to study the specific functions of individual genes, replicate them, and isolate them by enzymatically cleaving DNA into smaller fragments. This process has significantly accelerated progress in genetic engineering, molecular biology, and cloning research. In addition, the global rise in infectious diseases has further amplified the need for novel vaccine development. Recombinant vaccines designed using gene cloning technology can express targeted antigens, thereby stimulating more precise immune responses while also minimizing side effects compared to conventional vaccines.

The DNA and gene cloning services industry is undergoing rapid innovation, primarily driven by technological advancements in molecular cloning, recombinant DNA methods, and the rising clinical application of gene therapies. A growing number of research organizations, pharmaceutical companies, and biotechnology firms are adopting advanced DNA cloning technologies, which is opening new avenues for providers offering services such as gene synthesis, custom cloning, sub-cloning, and related applications. Alongside this, the market is also characterized by moderate but strategic merger and acquisition (M&A) activity. This trend is motivated by companies seeking to consolidate their position, strengthen technological capabilities, and achieve a competitive edge in an expanding industry. Furthermore, collaborations and partnerships are becoming increasingly common, as market participants aim to broaden their service portfolios and meet the growing demand resulting from advancements in recombinant DNA and molecular technologies.

Key Market Trends & Insights:

• Regional Outlook: North America dominated the global market in 2023, accounting for 40.98% of total revenue, supported by advanced healthcare infrastructure, strong research funding, and the presence of leading biotechnology companies. Meanwhile, the Asia Pacific market is expected to grow at the fastest rate, registering a projected CAGR of 16.76% from 2024 to 2030, driven by expanding research activities, rising healthcare expenditure, and increasing biotech investments in countries such as China and India.
• By Service: The gene synthesis services segment held the largest revenue share of 40.22% in 2023, reflecting its wide applications in genetic research and therapeutic development. However, the custom cloning services segment is projected to experience the fastest CAGR of 16.49% during the forecast period, owing to growing demand for tailor-made solutions in both academic and commercial research.
• By Application: DNA sequencing dominated with the highest revenue share of 39.51% in 2023, supported by its critical role in analyzing genetic information and enabling precision medicine. On the other hand, the mutagenesis segment is anticipated to record notable growth between 2024 and 2030 as researchers increasingly rely on this technique to study gene function and protein engineering.
• By End Use: Academic and research institutes emerged as the leading end-use segment, contributing 38.41% of market revenue in 2023, driven by continuous government and institutional funding for genetic studies. Looking ahead, the CROs (Contract Research Organizations) and CMOs (Contract Manufacturing Organizations) segment is forecasted to grow at the fastest CAGR of 16.55% from 2024 to 2030, as outsourcing trends gain momentum among pharmaceutical and biotech companies to optimize costs and accelerate R&D timelines.

Order a free sample PDF of the DNA And Gene Cloning Services Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2023 Market Size: USD 2.51 Billion
• 2030 Projected Market Size: USD 6.82 Billion
• CAGR (2024-2030): 15.43%
• North America: Largest market in 2023

Key Players

The following are the leading companies in the DNA and gene cloning services market. These companies collectively hold the largest market share and dictate industry trends.

• Bio-Techne
• Charles River Laboratories
• Eurofins Scientific
• GenScript
• Danaher Corporation
• Syngene International Limited
• Twist Bioscience
• Thermo Fisher Scientific Inc.
• Merck KGaA
• Curia Global, Inc.

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

The DNA and gene cloning services market is on a strong growth trajectory, fueled by continuous advancements in genetic engineering, the increasing adoption of gene therapy, and the rising need for personalized medicine. With expanding applications in vaccine development, drug discovery, and precision diagnostics, cloning technologies are becoming indispensable to both research and clinical practices. North America currently dominates due to advanced infrastructure and strong biotech presence, while Asia Pacific is expected to witness the fastest growth supported by growing investments and expanding research capabilities. Service providers are increasingly focusing on innovation, collaborations, and custom solutions to cater to diverse industry needs. Although the market faces challenges such as high costs and the need for strict regulatory compliance, the rapid pace of technological progress and expanding end-use applications are expected to outweigh these barriers. Overall, the industry is positioned for sustained expansion, offering significant opportunities for biotechnology firms, research institutions, and healthcare providers worldwide.